# Pharming Group N.V. ADS each representing 10 (PHAR)

Source: https://www.quantisnow.com/company/PHAR
Generated: 2026-11-13T03:47:08.692Z

- Ticker: PHAR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001828316
- Website: pharming.com

## About

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

## Latest PHAR news and filings

- 2026-11-11 07:00 UTC [Conference Announcement] [Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London](https://www.quantisnow.com/insight/pharming-to-participate-in-fireside-chat-at-jefferies-global-healthcare-6785074)
- 2026-11-06 11:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6777800)
- 2026-11-06 06:00 UTC [MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.](https://www.quantisnow.com/insight/mhra-approves-pharmings-joenja-leniolisib-as-first-treatment-specifically-for-6777650)
- 2026-10-27 11:11 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6758464)
- 2026-10-27 06:00 UTC [Earnings Date] [Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November](https://www.quantisnow.com/insight/pharming-group-reports-third-quarter-2026-financial-results-strong-revenue-6758154)
- 2026-10-22 11:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6754340)
- 2026-10-22 05:00 UTC [Earnings Date] [Pharming Group announces third quarter 2026 revenues above market expectations](https://www.quantisnow.com/insight/pharming-group-announces-third-quarter-2026-revenues-above-market-expectations-6754015)
- 2026-10-14 10:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6745758)
- 2026-10-14 06:00 UTC [Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026](https://www.quantisnow.com/insight/pharming-presents-positive-phase-ii-topline-data-for-leniolisib-in-6745674)
- 2026-09-29 10:40 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6728297)
- 2026-09-29 05:00 UTC [Leadership Update] [Pharming announces CEO transition](https://www.quantisnow.com/insight/pharming-announces-ceo-transition-6728183)
- 2026-09-25 15:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6726223)
- 2026-09-25 14:30 UTC [Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS](https://www.quantisnow.com/insight/pharming-announces-us-fda-acceptance-and-priority-review-of-snda-6726209)
- 2026-09-22 10:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6722226)
- 2026-09-22 05:00 UTC [Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026](https://www.quantisnow.com/insight/pharming-announces-positive-phase-ii-topline-data-for-leniolisib-in-6722067)
- 2026-09-11 18:59 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6712833)
- 2026-09-11 18:00 UTC [FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.](https://www.quantisnow.com/insight/fda-approves-pharmings-joenja-as-first-treatment-for-children-with-6712781)
- 2026-09-09 06:00 UTC [Conference Announcement] [Pharming Group to participate in September investor conferences](https://www.quantisnow.com/insight/pharming-group-to-participate-in-september-investor-conferences-6708962)
- 2026-08-13 10:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6679033)
- 2026-08-13 05:00 UTC [Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older](https://www.quantisnow.com/insight/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-6678925)
- 2026-08-04 06:00 UTC [Conference Announcement] [Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference](https://www.quantisnow.com/insight/pharming-group-to-participate-in-canaccord-genuity-46th-annual-growth-6660625)
- 2026-07-30 10:07 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6654664)
- 2026-07-30 05:00 UTC [Earnings Date] [Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use](https://www.quantisnow.com/insight/pharming-reports-second-quarter-and-first-half-2026-financial-results-6654529)
- 2026-07-16 06:00 UTC [Earnings Date] [Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30](https://www.quantisnow.com/insight/pharming-group-to-report-second-quarter-and-first-half-2026-6638764)
- 2026-06-04 10:09 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6588418)
- 2026-06-04 05:00 UTC [Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS](https://www.quantisnow.com/insight/pharming-announces-us-fda-acceptance-of-snda-resubmission-for-joenja-6588339)
- 2026-06-02 06:00 UTC [Conference Announcement] [Pharming Group to participate in Fireside Chat at  2026 Jefferies Global Healthcare Conference in New York](https://www.quantisnow.com/insight/pharming-group-to-participate-in-fireside-chat-at-2026-jefferies-6582850)
- 2026-05-28 14:52 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6576619)
- 2026-05-22 20:26 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6570022)
- 2026-05-22 19:30 UTC [European Commission grants marketing authorization to Pharming's Joenja® (leniolisib) – the first approved treatment for APDS in the European Union](https://www.quantisnow.com/insight/european-commission-grants-marketing-authorization-to-pharmings-joenja-leniolisib-the-6569413)
- 2026-05-07 10:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6536978)
- 2026-05-07 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6536963)
- 2026-05-07 05:05 UTC [Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders](https://www.quantisnow.com/insight/pharming-group-announces-presentations-at-cis-2026-annual-meeting-including-6536848)
- 2026-05-07 05:00 UTC [Earnings Date] [Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026](https://www.quantisnow.com/insight/pharming-group-reports-first-quarter-2026-financial-results-on-track-6536846)
- 2026-04-23 06:00 UTC [Earnings Date] [Pharming Group to report first quarter 2026 financial results and provide business update on May 7](https://www.quantisnow.com/insight/pharming-group-to-report-first-quarter-2026-financial-results-and-6511192)
- 2026-04-16 11:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6502212)
- 2026-04-13 14:24 UTC [Amendment: SEC Form 20-F/A filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/amendment-sec-form-20-fa-filed-by-pharming-group-nv-ads-6497559)
- 2026-04-10 12:34 UTC [Analyst Coverage Initiated] [Canaccord Genuity initiated coverage on Pharming Group N.V. with a new price target](https://www.quantisnow.com/insight/canaccord-genuity-initiated-coverage-on-pharming-group-nv-with-a-6495749)
- 2026-04-07 06:00 UTC [Conference Announcement] [Pharming Group to participate in April investor conferences](https://www.quantisnow.com/insight/pharming-group-to-participate-in-april-investor-conferences-6490072)
- 2026-04-02 10:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-pharming-group-nv-ads-each-6483163)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/PHAR
- Earnings history: https://www.quantisnow.com/earnings/PHAR
- Dividend history: https://www.quantisnow.com/dividends/PHAR
- Insider transactions: https://www.quantisnow.com/insiders/PHAR
- Options chain: https://www.quantisnow.com/options/PHAR
- SEC 8-K filings only: https://www.quantisnow.com/company/PHAR/8-k
- RSS and alerts for PHAR: https://www.quantisnow.com/docs/rss-feeds.md